OP-724 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 93 | 原発性胆汁性胆管炎 | 1 |
93. 原発性胆汁性胆管炎
臨床試験数 : 282 / 薬物数 : 245 - (DrugBank : 56) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 113
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04047160 (ClinicalTrials.gov) | August 29, 2019 | 30/7/2019 | Safety, Tolerability of OP-724 in Patients With Primary Biliary Cholangitis (Phase I) | An Open-Label, Dose-Finding Study for the CBP / ß-catenin Inhibitor OP-724 in Patients With Primary Biliary Cholangitis (Phase I) | Primary Biliary Cholangitis (PBC);Liver Cirrhosis, Biliary | Drug: OP-724 | Kiminori Kimura, MD | Ohara Pharmaceutical Co., Ltd.;Japan Agency for Medical Research and Development | Active, not recruiting | 20 Years | 74 Years | All | 12 | Phase 1 | Japan |